BIODESIX, INC. Comprehensive Income
BIODESIX, INC. (BDSX) reported Comprehensive Income of $0 for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-12-10.
Discontinued › Income Statement
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2020-12-10
- 2020-09-30: Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month $0.00.
- 2019-09-30: Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month $0.00.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month |
|---|---|
| 2020-09-30 | $0.00 10-Q · filed 2020-12-10 |
| 2019-09-30 | $0.00 10-Q · filed 2020-12-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |